InO + TKI has robust activity but limited toxicity when drugs are given sequentially. Great option for older adults with Ph+ ALL in frontline.
Caner Saygin, MD
Got to present our Ph+ ALL TKI plus inotuzumab study at #ASH25! Highlights:
-all patients achieved MR4 or NGS negativity
-VOD seen with initial schema, updated schema splitting InO and TKI had no VOD
-80% OS and 76% EFS with no CNS relapse, one systemic relapse, and no allo-HCT
